Measles Virus for Cancer Therapy
Measles virus offers an ideal platform from which to build a new generation of safe, effective oncolytic viruses. Occasional so-called spontaneous tumor regressions have occurred during natural measles infections, but common tumors do not express SLAM, the wild-type MV receptor, and are therefore not susceptible to the virus. Serendipitously, attenuated vaccine strains of measles virus have adapted to use CD46, a regulator of complement activation that is expressed in higher abundance on human tumor cells than on their nontransformed counterparts.For this reason, attenuated measles viruses are potent and selective oncolytic agents showing impressive antitumor activity in mouse xenograft models. The viruses can be engineered to enhance their tumor specificity, increase their antitumor potency, and facilitate noninvasive in vivo monitoring of their spread. A major impediment to the successful deployment of oncolytic measles viruses as anticancer agents is the high prevalence of preexisting anti-measles immunity, which impedes bloodstream delivery and curtails intratumoral virus spread. It is hoped that these problems can be addressed by delivering the virus inside measles-infected cell carriers and/or by concomitant administration of immunosuppressive drugs. From a safety perspective, population immunity provides an excellent defense against measles spread from patient to carers and, in 50 years of human experience, reversion of attenuated measles to a wild-type pathogenic phenotype has not been observed. Clinical trials testing oncolytic measles viruses as an experimental cancer therapy are currently underway.
Unable to display preview. Download preview PDF.
- Anonymous (1996) Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection. MMWR Morb Mortal Wkly Rep 45:603–606Google Scholar
- Griffin D (2001) Measles virus. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (eds) Fields virology, 5th edn, Lippincott Williams ' Wilkins, Philadelphia, pp 1551–1585Google Scholar
- Hill DL (1975) Pharmacology. In: Thomas CC (ed) A review of cyclophosphamide. Thomas Publishers, Springfield, IL pp 60–85Google Scholar
- Katz S (1996) The history of measles virus and the development and utilization of measles virus vaccines. In: Plotkins S, Fantini B (eds) Vaccinia, vaccination and vaccinology: Jenner Pasteur and their successors. Elsevier, Paris, pp 265–270Google Scholar
- Lecouturier V, Fayolle J, Caballero M, et al (1996) Identification of two amino acids in the hemag-glutinin glycoprotein of measles virus (MV) that govern hemadsorption HeLa cell fusion, and CD46 downregulation: phenotypic markers that differentiate vaccine and wild-type MV strains. J Virol 70:4200–4204PubMedGoogle Scholar
- Ordman CW, Jennings CG, Janeway CA (1944) Chemical clinical, and immunological studies on the products of human plasma fractionation. XII. The use of concentrated normal human serum gamma globulin (human immune serum globulin) in the prevention and attenuation of measles. J Clin Invest 23:541–549PubMedCrossRefGoogle Scholar
- Peng KW, Facteau S, Wegman T, et al (2002a) Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 62:4656–4662Google Scholar
- Schwarz AJ, Boyer PA, Zirbel LW, et al (1960) Experimental vaccination against measles. I. Tests of live measles and distemper vaccine in monkeys and two human volunteers under laboratory conditions. JAMA 173:861–867Google Scholar
- Simpson KL, Jones A, Norman S, et al (1997) Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease. Am J Pathol 151:1455–1467PubMedGoogle Scholar
- Steinberg A (2001) Cyclophosphamide. In: Austen K et al. (eds) Therapeutic immunology. Blackwell, Malden, pp 31–50Google Scholar
- Varsano S, Rashkovsky L, Shapiro H, et al (1998) Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin Exp Immunol 113:173–182PubMedCrossRefGoogle Scholar